Maja Lusk
Family · Salt Lake City, UTNPI 1083008601
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 61 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$191
- Daiichi Sankyo Inc.$161
- AstraZeneca$116
- Eisai Inc.$85
- GSK$81
- Merck$66
- plus $565 from 20 others
What the payments were for
- Food & beverage$1,265100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $191 |
| Daiichi Sankyo Inc. | 7 | $161 |
| AstraZeneca | 6 | $116 |
| Eisai Inc. | 4 | $85 |
| GSK | 4 | $81 |
| Merck | 3 | $66 |
| Pfizer | 2 | $50 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Johnson & Johnson | 2 | $44 |
| Rigel Pharmaceuticals, Inc. | 2 | $42 |
| Bristol Myers Squibb | 2 | $39 |
| Array Biopharma Inc | 2 | $36 |
| Incyte Corporation | 2 | $36 |
| EMD Serono, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Amgen | 1 | $27 |
| AbbVie | 1 | $25 |
| Sanofi | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $14 |
| CTI Biopharma Corp. | 1 | $13 |
| Seagen Inc. | 1 | $13 |
How this compares
$1,265 in reported general payments places this provider in the 75th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 15 | $378 |
| Hydroxyurea | 18 | $289 |
| Prochlorperazine Maleate | 15 | $182 |
Paid to pharmacies, not to this prescriber.
Other family in Salt Lake City
- Katrina BawdenSalt Lake City$395K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Kacie Doyle-DelgadoSalt Lake City$80K
- Melonie ThompsonSalt Lake City$45K
- Keisa LynchSalt Lake City$39K
- Christina CardonSalt Lake City$36K
- Jessica ArbogastSalt Lake City$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.